Can switching hormone therapy help when breast cancer progresses?
NCT ID NCT02738866
First seen Dec 16, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study looks at whether continuing the drug palbociclib but switching to a different hormone therapy (fulvestrant) can help people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to palbociclib and an aromatase inhibitor. About 60 participants will receive the new combination to see how long the cancer stays under control. The goal is to find a better treatment option after the first one stops working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network (AHN) - Allegheny General Hospital ONLY
Pittsburgh, Pennsylvania, 15212, United States
-
Anne Arundel Health System Research Institute, Inc.
Annapolis, Maryland, 21401, United States
-
Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Reading Hospital - McGlinn Cancer Institute
West Reading, Pennsylvania, 19611, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.